ChiCTR2300074531: A prospective, single-arm, multicenter clinical study of cadonilimab combined with surufatinib in the treatment of progress advanced soft tissue sarcoma after system chemotherapy |
|
|
| Not yet recruiting | N/A | 99 | | ① Cadonilimab was administered by intravenous infusion at a dose of 6mg/kg every 2 weeks. ② Surufatinib capsules: 200mg (4 capsules) each time, can be taken with a low-fat meal or orally on an empty stomach, once a day, continuous medication. | Shanghai Tongren Hospital; Shanghai Tongren Hospital, cadonilimab：Kangfang Biopharmaceutical Co., Ltd surufatinib：Hutchison MediPharma Co., Ltd | soft tissue sarcoma | | | | |
